SUMMARY REPORT OF THE 17th ED EXPERT GROUP MEETING

The 1st virtual meeting of the Endocrine Disruptor Expert Group (ED EG) was hosted by ECHA on 1 October 2020. The participants actively contributed to the discussions also in the new setup, and provided scientific advice on the ED assessments carried out by the Member States. The group discussed five substances in closed and open sessions (see also table below), received reports of three written procedures (WP). Further actions to help ensure the EG maximises its support to the regulatory processes were also discussed and agreed.

The meeting was attended by 53 participants representing 16 Member States and EEA countries (AT, BE, CZ, DE, DK, EL, ES, FI, FR, IE, LT, NL, NO, SE, SK, SI), Switzerland, EFSA, European Commission and 4 accredited stakeholder organisations (CHEM Trust, Heal, HSI, CEFIC).

Main outcomes of the substance discussions

Closed session

- 2-ethylhexyl trans-4-methoxycinnamate (OMC) and isopentyl p-methoxycinnamate (IPMC) (CoRAP 2016 – follow-up evaluation): The ED EG agreed that the FSDT and AMA performed on OMC following a first decision were not sufficient and more testing will be needed on IPMC to clarify the ED concern for both substances. There was large support to first carry out FSDT with IPMC, and then consider the applicability of read across between the two substances.

- 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2-naphthyl)ethan-1-one (tonalide) (CoRAP 2020): The ED EG supported requesting FSDT including measurements of T hormones and VTG. If FSDT is inconclusive, the ED EG advised potential follow-up with LAGDA. In relation to human health, the assessment of the EAS modalities needs refinement. T modality will be addressed by the ED EG in a writing.

- (±)-1,7,7-trimethyl-3-[(4-methylphenyl)methylene]bicyclo[2.2.1]heptan-2-one (4-MBC) (CoRAP 2020): The ED EG agreed that there is a concern due to the ED properties for the environment. There was a large support to request FSDT, and if inconclusive follow up by LAGDA. FSDT should include T sensitive endpoints and histopathology for gonad, liver and kidney.

Open session

- 3-iodo-2-propynyl butylcarbamate (IPBC) (Biocide): The evaluating CA proposed that the substance is not an ED for HH. There were diverging views on the interpretation of the presented data and the assessment was considered to need further refinement. The evaluating MS requested further advice on the human health ED assessment from the ED EG in writing. The substance will be discussed again in the next ED EG meeting.

General ED-related topics

ECHA presented an Expert Group Action Plan proposing actions which should help the EG to maximise its support of the regulatory processes. The actions, which included increased use of ICT, as well as improved planning, documentation and information flow, were discussed and agreed. Some additional suggestions from the group were also discussed. The importance of

having at least one physical meeting per year was emphasized by many participants, if possible.

Next ED EG meeting will take place via Webex on 17-18 November 2020. Tentative meeting dates in 2021 are 13-14 April, 5-6 October, and 16-17 November.

Substances discussed at the 17th ED EG meeting:

MS	EC number	Substance name	Outcome of the discussion	Session	Notes
DK	259-627-5	3-iodo-2-propynyl butylcarbamate (IPBC)	Refine assessment	open	Biocidal active substance
DE	216-133-4 244-240-6	1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2-naphthyl)ethan-1-one (tonalide)	Testing needed	closed	CoRAP 2020
DE	253-242-6	(±)-1,7,7-trimethyl-3-[(4-methylphenyl)methylene]bicyclo[2.2.1]heptan-2-one (4-MBC)	Testing needed	closed	CoRAP 2020
DE	629-661-9	2-ethylhexyl trans-4-methoxycinnamate (OMC)	Refine assessment	closed	CoRAP 2016
DE	275-702-5	isopentyl p-methoxycinnamate (IPMC)	Testing needed	closed	CoRAP 2016